All Updates

All Updates

icon
Filter
Product updates
Cardio Diagnostics launches PrecisionCHD
Precision Medicine
Feb 28, 2023
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Partnerships
Product updates
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Precision Medicine

Precision Medicine

Feb 28, 2023

Cardio Diagnostics launches PrecisionCHD

Product updates

  • Cardio Diagnostics Holdings, a genetic testing, precision cardiovascular medicine company, announced the launch of PrecisionCHD, a combined genetic and epigenetic blood test that can detect coronary heart disease at an early stage.  

  • Precision CHD is the company’s second clinical test after Epi+GenCHD and is built using the AI-driven Integrated Epigenetic-genetic Engine. Both tests cover all aspects of coronary heart disease, ranging from evaluating the likelihood of developing it for preventive purposes, to early detection.

  • Additionally, Precision CHD includes an Actional Clinical Intelligence platform, which is exclusively available for healthcare providers. This platform assesses a patient’s distinctive biomarker profile with controllable risk factors including diabetes, high blood pressure, high cholesterol levels, and smoking, which are recognized as significant contributors to coronary heart disease. PrecisionCHD has a sensitivity of over 75% for detecting coronary heart disease in both females and males and can be conducted in healthcare facilities or remotely using a combination of at-home sampling and telehealth options. 

  • Cardio Diagnostics Holdings is a company that specializes in precision cardiovascular medicine and uses AI to enhance accessibility, personalization, and accuracy in preventing and detecting cardiovascular disease. The company was founded with the aim of promoting and selling clinical tests that use a distinctive Integrated Genetic-epigenetic Engine powered by AI.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.